Assertio Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $29,222 | $26,488 | $32,182 | $29,204 |
Gross Profit | 18,545 | 18,702 | 20,571 | 21,654 |
EBITDA | -6,379 | -13,233 | -3,275 | 4,595 |
EBIT | -15,646 | -22,502 | -9,986 | -2,116 |
Net Income | -16,352 | -13,051 | -10,476 | -2,921 |
Net Change In Cash | 29,222 | 26,488 | 32,182 | 29,204 |
Free Cash Flow | 19,091 | -12,538 | 11,548 | -35 |
Cash | 47,086 | 35,004 | 50,588 | 37,981 |
Basic Shares | 95,970 | 95,677 | 95,509 | 95,352 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $124,961 | $152,069 | $156,234 | $111,014 |
Gross Profit | 85,734 | 125,049 | 137,486 | 95,182 |
EBITDA | -24,476 | -222,447 | 72,535 | 38,781 |
EBIT | -24,568 | -250,676 | 39,127 | 9,667 |
Net Income | -21,581 | -331,942 | 109,625 | -1,281 |
Net Change In Cash | 124,961 | 152,069 | 156,234 | 111,014 |
Free Cash Flow | 26,408 | 48,976 | 78,324 | 5,470 |
Cash | 50,588 | 73,441 | 64,941 | 36,810 |
Basic Shares | 95,271 | 71,031 | 54,669 | 43,169 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.02 |
2025-03-31 | -$0.04 |
2024-12-31 | -$0.03 |
